ADVENTRX to Present at Rodman & Renshaw Techvest 2nd Annual Global Healthcare Conference on May 5.SAN DIEGO -- ADVENTRX Pharmaceuticals, Inc. (AMEX AMEX
See: American Stock Exchange :ANX ANX Annex
ANX Adventrx Pharmaceuticals (San Diego, CA)
ANX Automotive Network Exchange (AIAG)
ANX Advanced Network Exchange
ANX Ascending Node Crossing (satellites) ) today announced that Evan M. Levine, president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , will present at the Rodman & Renshaw Techvest 2nd Annual Global Healthcare Conference on Thursday, May 5 at 9:25 a.m. Central European Time/ 3:25 a.m. Eastern Time.
A link to the Company's live audio webcast and slide presentation will be available via the "Investors" section of the Company's Web site at http://www.adventrx.com/investors/events.htm. An archived presentation will be available for 30 days.
The conference will be held at the InterContinental Hotel in Paris. To register for this conference or for additional information, visit www.rodmanandrenshaw.com. Attendees will include institutional investors and venture capitalists.
ADVENTRX Pharmaceuticals is a biopharmaceutical research and development company focused on introducing new technologies for anticancer and antiviral treatments that improve the performance of existing drugs and address significant problems such as drug metabolism Drug Metabolism/Interactions Definition
Drug metabolism is the process by which the body breaks down and converts medication into active chemical substances.
Drugs can interact with other drugs, foods, and beverages. , bioavailability bioavailability /bio·avail·a·bil·i·ty/ (bi?o-ah-val?ah-bil´i-te) the degree to which a drug or other substance becomes available to the target tissue after administration.
n. and resistance. More information can be found on the Company's Web site at www.adventrx.com.
Forward Looking Statement
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors, including uncertainties inherent in the drug development process, the timing and success of clinical trials, the validity of research results, and the receipt of necessary approvals from the FDA FDA
Food and Drug Administration
n.pr See Food and Drug Administration.
n.pr the abbreviation for the Food and Drug Administration. and other regulatory agencies. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" in the Company's last annual report on Form 10-KSB, as well as other reports that the Company files from time to time with the Securities and Exchange Commission. All forward-looking statements are qualified in their entirety by this cautionary statement. The Company undertakes no obligation to release publicly any revisions, which may be made to reflect events or circumstances after the date hereof.